Tiziana Life Sciences Ltd (TLSA)
NASDAQ: TLSA · Real-Time Price · USD
2.060
-0.010 (-0.48%)
At close: Sep 26, 2025, 4:00 PM EDT
2.020
-0.040 (-1.94%)
After-hours: Sep 26, 2025, 7:44 PM EDT
Tiziana Life Sciences Employees
Tiziana Life Sciences had 9 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
9
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,318,111
Market Cap
229.61M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
TLSA News
- 3 days ago - Tiziana Life Sciences Announces Poster Presentation on Intranasal Foralumab Clinical Trial at the 41st ECTRIMS Congress - GlobeNewsWire
- 12 days ago - Department of Defense Awards Grant to Advance Tiziana Life Sciences Intranasal Anti-CD3 Therapy for Spinal Cord Injury - GlobeNewsWire
- 18 days ago - Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer - GlobeNewsWire
- 22 days ago - Tiziana Life Sciences Announces Purchase of Shares by Chairman - GlobeNewsWire
- 6 weeks ago - Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab for Multiple System Atrophy - GlobeNewsWire
- 6 weeks ago - FDA Approves Tiziana Life Sciences Phase 2 IND for Multiple System Atrophy - GlobeNewsWire
- 2 months ago - Tiziana Life Sciences Announces Immunologic Analysis of Nasal Foralumab in Moderate Alzheimer's Patient - GlobeNewsWire
- 3 months ago - Tiziana: Scope Of Foralumab Goes Beyond That Of Multiple Sclerosis Targeting - Seeking Alpha